NCT03431571 (V1601CI) is a NA clinical trial of ReLEx SMILE in Hypermetropia, sponsored by Carl Zeiss Meditec AG.

Who is sponsoring NCT03431571?

NCT03431571 is sponsored by Carl Zeiss Meditec AG.

What drugs are being tested in NCT03431571?

Interventions in NCT03431571: ReLEx SMILE.

What condition does NCT03431571 study?

NCT03431571 studies Hypermetropia.

Is NCT03431571 still recruiting?

NCT03431571 is currently status unknown. Last updated 24 February 2020.

Last reviewed 2020-02-24 · How we verify

NCT03431571: V1601CI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia

Status unknown NA Last updated 24 February 2020

What this trial tests

NA trial testing ReLEx SMILE in Hypermetropia in 374 participants. Status unknown.

Timeline

5 July 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Carl Zeiss Meditec AG
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	374
Start date	5 July 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	8 locations across France, United Kingdom, Germany, Czechia, China, India

Drugs / interventions tested

ReLEx SMILE

Conditions studied

Hypermetropia — all drugs for Hypermetropia →

Sponsor

Carl Zeiss Meditec AG — full company profile →

Who can join

18 and older, any sex, with Hypermetropia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The correction of farsightedness using ReLEx SMILE for hyperopia is focus of this investigation. The objective is to evaluate the safety and effectiveness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypermetropia

Currently open trials in the same condition.

NCT06484257 — Comparison Between Myopia Versus Hypermetropia With Progressive Addition Lenses in Computer Users · NA · active not recruiting
NCT04692012 — Treatment of Residual Hypermetropic Refraction on Pseudophakic Patients Using Allogenic Fresh Myopic Lenticule · NA · active not recruiting

Other Carl Zeiss Meditec AG trials

Trials by the same sponsor.

NCT07471295 — Toric Performance And Constant Evaluation · Phase 4 · not yet recruiting
NCT07297719 — Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation · completed
NCT06192901 — Safety and Performance of Hydrophobic and Hydrophilic Intraocular Lenses After Bilateral Cataract Surgery · completed
NCT06247683 — Study to Confirm Safety and Performance of a New Multifocal IOL · NA · completed
NCT05646004 — 621 Real World Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03431571 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carl Zeiss Meditec AG
Last refreshed: 24 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03431571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing